{"id":"placebo-to-match-ruxolitinib","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1287854","moleculeType":"Small molecule","molecularWeight":"306.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not have a specific mechanism of action, but rather serves as a control group in clinical trials to compare the efficacy of ruxolitinib.","oneSentence":"This drug is a placebo used to match the effects of ruxolitinib.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:43.331Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelofibrosis"}]},"trialDetails":[{"nctId":"NCT07357727","phase":"PHASE3","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-15","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)","enrollment":460},{"nctId":"NCT06832618","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-17","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT04603495","phase":"PHASE3","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-09","conditions":"Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":430},{"nctId":"NCT04562389","phase":"PHASE3","title":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-03-11","conditions":"Myelofibrosis","enrollment":353},{"nctId":"NCT04896385","phase":"PHASE2","title":"A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-06-23","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT04921969","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2021-07-19","conditions":"Atopic Dermatitis","enrollment":330},{"nctId":"NCT01969838","phase":"PHASE3","title":"Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis","status":"COMPLETED","sponsor":"Sierra Oncology LLC - a GSK company","startDate":"2013-12-06","conditions":"Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis","enrollment":432},{"nctId":"NCT04377620","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2020-05-24","conditions":"COVID-19","enrollment":211},{"nctId":"NCT04362137","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-05-02","conditions":"Cytokine Storm (Covid-19)","enrollment":432},{"nctId":"NCT00952289","phase":"PHASE3","title":"COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2009-08","conditions":"MPN (Myeloproliferative Neoplasms)","enrollment":309},{"nctId":"NCT02119650","phase":"PHASE2","title":"Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2014-02-11","conditions":"NSCLC (Non-small Cell Lung Carcinoma)","enrollment":76},{"nctId":"NCT02119676","phase":"PHASE2","title":"Study of Ruxolitinib in Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2014-03","conditions":"CRC (Colorectal Cancer)","enrollment":396},{"nctId":"NCT02119663","phase":"PHASE3","title":"A Study of Ruxolitinib in Pancreatic Cancer Patients","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2014-06","conditions":"Pancreatic Cancer","enrollment":86},{"nctId":"NCT02120417","phase":"PHASE2","title":"A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2014-05","conditions":"Breast Cancer","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match ruxolitinib","genericName":"Placebo to match ruxolitinib","companyName":"Sierra Oncology LLC - a GSK company","companyId":"sierra-oncology-llc-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a placebo used to match the effects of ruxolitinib. Used for Myelofibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}